| Study | Arm Dose mg/Day (N) | Duration (Weeks) | Population Trauma Type | Baseline PTSD Severitya | Mean Age (Y) | % Female | % Non-white | Risk of Bias |
|---|---|---|---|---|---|---|---|---|
| Raskind et al., 200374 | Prazosin 2 to 10 mg (5) Placebo (5) | 20 | Male Combat veterans | 79.1 to 83.6 | 53 | 0 | NR | Medium |
| Raskind et al., 200775 | Prazosin 2 to 15 mg (20) Placebo (20) | 8 | Male and female Combat veterans | 70.0 | 56 | 5 | 35 | Medium |
| Raskind et al., 201376 | Prazosin 1 mg titrated to a max of 20 mg for men or 10 mg for women (32) Placebo (35) | 15 | Veterans Active-duty soldiers, Combat trauma | 77.3 to 85.7 | 30 | 15 | 37 | Medium |
Data reported are mean CAPS or range of mean CAPS scores across groups unless otherwise specified.
Note: When mean data for baseline PTSD severity were not reported for the total sample but were presented for each study arm, we provide the range across arms.
CAPS = Clinician-Administered PTSD Scale; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = year.
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.